Real-World Effectiveness of Burosumab Versus Oral Phosphate and Active Vitamin D in Adults with X-Linked Hypophosphatemia (XLH): A 3-Year Follow-Up of the XLH Disease Monitoring Program

Clicks: 13
ID: 329538
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #78 of 133 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 133 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract X-linked hypophosphatemia (XLH) is a progressive disease in which excess FGF23 causes renal phosphate wasting, leading to hypophosphatemia. Consequences in adults include osteomalacia, fractures, pseudofractures, joint dysfunction, pain, and impaired mobility. Treatments for XLH are the anti-FGF23 antibody burosumab and active forms of vitamin D alone or in combination with oral phosphate (Pi/D). Randomized studies comparing burosumab with Pi/D in adults with XLH are lacking. We present a 3-yr follow-up analysis evaluating real-world effectiveness of burosumab versus Pi/D based on biochemistry and standardized symptom assessments (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) using data from the XLH Disease Monitoring Program (DMP; NCT03651505), a prospective, Americas-based study. Adults with XLH initiated burosumab between baseline and the year 1 visit (N = 54) or reported being on Pi/D therapy at enrollment (N = 55) were included. After adjusting for baseline differences using inverse probability of treatment weighting, the data showed a significantly higher mean (SD) change from baseline in serum phosphate with burosumab versus Pi/D (year 1: 0.8 [0.8] vs 0.1 [0.7] mg/dL; year 3: 0.6 [0.8] vs 0.1 [0.7] mg/dL, both p < .001). A higher proportion of burosumab versus Pi/D participants achieved serum phosphate levels above the lower limit of normal (2.5 mg/dL; year 1: 70.5% vs 18.8%; year 3: 60.8% vs 25.0%, both p < .001). At year 1, changes from baseline in WOMAC pain (−6.3 [27.7] vs 2.1 [22.4], p = .055), physical function (−6.4 [19.1] vs 0.1 [29.0], p = .122), and stiffness (−11.1 [32.1] vs −2.3 [33.7], p = .073) were not statistically significant between cohorts, but were significant at year 3 (pain: −9.8 [22.6] vs 3.3 [24.1], p < .001; physical function: −10.0 [25.7] vs 3.3 [24.7], p = .001; stiffness: −15.2 [29.5] vs −3.7 [31.4], p = .016). In this real-world analysis of adults with XLH over a 3-yr follow-up, burosumab treatment was associated with improved serum phosphate and patient-reported outcomes versus Pi/D.
Reference Key
openalex_W7214116152 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Steven Wai Ing, Sasigarn Arunchaiya Bowden, Kathryn McCrystal Dahir, Pablo F Florenzano, Ingrid A. Holm, Aneal Khan, Michael A. Levine, Carolina de Souza Moreira, Laila Tabatabai, Thomas Joseph Weber, Shubham Tewari, Ben Johnson, Marc Vincent, Jaimin Patel, Lak Nilusha Kotinkaduwa, Zhiyi Li, Leanne Marie Ward, Erik Allen Imel, DMP Investigators, Andrea Arcari, Oscar Brunetto, Walter Douthat, Regina Matsunaga Martin, Carolina Aguiar Moreira, Sanjukta Basak, Frank Rauch, Marie Eve Robinson, Sarah Khan, Leanne Ward, Pablo Florenzano, Richard Baquero-Rodríguez, Adriana Meza-Martinez, Ambika P. Ashraf, Sasigarn Bowden, Bradley P. Dixon, Thomas Carpenter, Janet Crane, Kathryn McCrystal Dahir, Ian Glass, Gary Gottesman, Eric Gyuricsko, Ingrid Holm, Erik Imel, Steven Ing, Suzanne Jan de Beur, Michael Levine, Neil Paloian, Anthony Portale, David Rodriguez-Buritica, Anna Ryabets‐Lienhard, Jill Simmons, Puja Singh, Laila Tabatabai, Halley Wasserman, Thomas Weber
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2026
DOI
10.1093/jbmr/zjag136
URL
https://doi.org/10.1093/jbmr/zjag136
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.